Erasca, Inc. (ERAS) DCF Valuation

Erasca, Inc. (Eras) ​​Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Erasca, Inc. (ERAS) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Erasca, Inc. (ERAS) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Ahorre tiempo y mejore la precisión con nuestra calculadora DCF (ERAS)! Utilizando datos de Real Erasca, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y valorar Erasca, Inc. como un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -13.0 -101.1 -121.9 -240.2 -121.3 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .3 .5 .8 2.6 3.7 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -13.3 -101.7 -122.8 -242.8 -125.0 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 50.4 118.7 459.2 435.6 312.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.4 .9 4.7 23.0 2.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.6 -38.7 -18.9 -16.6 -1.8 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -11.9 -173.1 -150.1 -238.2 -125.0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -10.8 -211.7 -164.3 -233.7 -144.1 -2.0 .0 .0 .0 .0
WACC, % 9.17 9.23 9.23 9.22 9.23 9.22 9.22 9.22 9.22 9.22
PV UFCF
SUM PV UFCF -1.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -37
Equity Value 35
Diluted Shares Outstanding, MM 150
Equity Value Per Share 0.24

What You Will Get

  • Comprehensive ERAS Financials: Access historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess Erasca's future performance.
  • User-Friendly Design: Designed for professionals but easy for newcomers to navigate.

Key Features

  • 🔍 Real-Life ERAS Financials: Pre-filled historical and projected data for Erasca, Inc. (ERAS).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Erasca’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Erasca’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • 1. Access the Template: Download and open the Excel file featuring Erasca, Inc.'s (ERAS) preloaded data.
  • 2. Modify Assumptions: Adjust critical inputs such as growth projections, WACC, and capital expenditures.
  • 3. See Results Instantly: The DCF model automatically calculates the intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation outcomes.
  • 5. Present with Assurance: Deliver professional valuation insights to back your decisions.

Why Choose This Calculator for Erasca, Inc. (ERAS)?

  • Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
  • Accurate Financials: Erasca’s historical and projected financial data preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessments of Erasca, Inc. (ERAS).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights to clients interested in Erasca, Inc. (ERAS) stock.
  • Students and Educators: Utilize real-world data to practice and instruct on financial modeling techniques.
  • Biotech Enthusiasts: Gain insights into how biotech firms like Erasca, Inc. (ERAS) are valued in the investment landscape.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Erasca, Inc. (ERAS) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Erasca, Inc. (ERAS).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.